Business Wire

SILVER-LAKE

22.6.2022 19:39:13 CEST | Business Wire | Press release

Share
Silver Lake Enters Into Definitive Agreement to Acquire a Majority Stake in Facile.it from EQT and Oakley Capital to Support Management in the Next Phase of Growth, Making Facile Italy’s Second Unicorn

Silver Lake, the global leader in technology investing, has today announced that it has entered into a definitive agreement to acquire a majority stake in Facile.it (“Facile”), the leading Italian online price comparison platform, from EQT VIII fund (“EQT Private Equity”) and Oakley Capital, a pan-European private equity firm. With the transaction, Facile will become the second Italian unicorn.

Tobias Stuber, CEO of Facile, said: “On behalf of the Facile management team and all employees, I would like to thank EQT for the successful, collaborative, and highly productive partnership over the past four years on our journey towards capitalizing further on our position as a landmark destination for Italy’s household spending. Thanks to EQT’s support, we are in an even better position today for the next phase of our growth with our new partner Silver Lake.”

Christian Lucas, Co-Head of Silver Lake EMEA, said: “Facile is an exceptional business with a differentiated and powerful value proposition for customers, channel partners and financial service providers. We are truly impressed by what Tobias and the rest of the team have built over the past years. The company is now Italy’s leading online destination for consumers to compare prices with a market-leading tech platform and unique omnichannel capabilities across its agent networks and stores.

Investing in high-growth and pioneering business models with differentiated technology capabilities is at the core of our mission. We look forward to partnering with Tobias and the rest of the management team to significantly invest in the business and drive further growth and value creation over the coming years by contributing our experience from investments in multiple similar businesses across Europe.”

Dominik Stein, Partner at EQT Private Equity, said: “Facile is a great example of how EQT can help unlock a company’s full potential by combining our local-with-locals approach and deep sector expertise, with our long experience from developing tech companies. EQT is proud of having been a part of Facile’s remarkable growth trajectory and development. We would like to thank the whole management team for the trusted partnership over the past four years. We would also like to thank our co-investor Oakley Capital, the Advisory Committee members and all employees for their daily commitment in making Facile the unique company it is today.”

Founded in 2008 and headquartered in Milan, Italy, Facile originated with pioneering the offering of motor insurance brokerage online, for which it is the clear market leader in Italy today. Over time, Facile successfully diversified its offering by adding new product lines including gas & power, broadband, mortgages, consumer loans and, more recently, a new car sales marketplace platform. Facile has built a market-leading brand through several years of successful investment resulting in unparalleled brand awareness and leading website traffic volumes in the Italian market. Facile also benefits from a scaled omni-channel distribution approach across its online channels, its network of owned stores as well as its networks of insurance and mortgage & consumer loan agents it collaborates with, enabled by a market-leading tech platform that benefits from years of significant investment.

Silver Lake will leverage its extensive experience in the field from its many investments into similar companies across Europe to support Facile’s management team in the next phase of growth. Silver Lake intends to continue to invest in and broaden Facile’s product range to help accelerate the company’s strong growth trajectory across its core verticals, its recently launched growth verticals as well as future potential new product launches to strengthen the value proposition to both Italian consumers and partners.

The transaction is subject to customary conditions and approvals and is expected to close in Q3 2022.

Morgan Stanley acted as the exclusive financial advisor, Simpson Thacher & Bartlett and BonelliErede as legal advisors to Silver Lake.

About Facile

Facile.it is the leading Italian Online Price Comparison platform, helping over 4 million customers every month to compare prices on key areas of their household spending, providing access to a wide product offering, helping them save time and money. The Company in 2021 generated approximately €140 million in revenue.

About Silver Lake

Silver Lake is a global technology investment firm, with more than $88 billion in combined assets under management and committed capital and a team of professionals based in North America, Europe and Asia. Silver Lake’s portfolio companies collectively generate nearly $254 billion of revenue annually and employ approximately 557,000 people globally.

About EQT

EQT is a purpose-driven global investment organization with €77 billion in assets under management across 36 active funds. EQT funds have portfolio companies in Europe, Asia-Pacific and the Americas with total sales of approximately €29 billion and more than 280,000 employees. EQT works with portfolio companies to achieve sustainable growth, operational excellence and market leadership.

About Oakley Capital

Founded in 2002, Oakley Capital is a pan-European private equity firm backing ambitious growth companies across three core sectors – Technology, Consumer and Education. Oakley is able to deliver differentiated investment opportunities and superior returns by leveraging its entrepreneurial mindset and deep sector expertise. The Oakley team works closely with a unique network of entrepreneurs and successful management teams to help source primary, proprietary opportunities and gain valuable insights into the businesses in which it invests. Its ability to overcome complexity, and a flexible approach to value creation, allows Oakley to support its portfolio companies to achieve sustainable growth.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye